Gestonorone | CAS#2137-18-0 | steroidal progestin

MedKoo Cat#: 561639 | Name: Gestonorone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gestonorone is a steroidal progestin of the 19-norprogesterone and 17α-hydroxyprogesterone groups that was never marketed.

Chemical Structure

Gestonorone

CAS#2137-18-0

Theoretical Analysis

MedKoo Cat#: 561639

Name: Gestonorone

CAS#: 2137-18-0

Chemical Formula: C20H28O3

Exact Mass: 316.2038

Molecular Weight: 316.44

Elemental Analysis: C, 75.91; H, 8.92; O, 15.17

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Gestonorone; 17alpha-Hydroxy-19-norprogesterone;

IUPAC/Chemical Name

(8R,9S,10R,13S,14S,17R)-17-Acetyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one

InChi Key

GTFUITFQDGVJSK-XGXHKTLJSA-N

InChi Code

InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1

SMILES Code

O=C1CC[C@]2([H])[C@@]3([H])CC[C@]4(C)[C@@](O)(C(C)=O)CC[C@@]4([H])[C@]3([H])CCC2=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 316.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Asadi E, Azodi-Deilami S, Abdouss M, Khaghani S. Cyproterone synthesis, recognition and controlled release by molecularly imprinted nanoparticle. Appl Biochem Biotechnol. 2012 Aug;167(7):2076-87. doi: 10.1007/s12010-012-9748-y. Epub 2012 Jun 5. PubMed PMID: 22669687. 2: O'Brien JM, Lewis DF. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies. J Reprod Med. 2009 Feb;54(2):73-87. Review. PubMed PMID: 19301570. 3: Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance. J Reprod Med. 2009 Feb;54(2):47-52. PubMed PMID: 19301566. 4: Gomez F, Ruiz P, Briceño F, Lopez R, Michan A. Treatment with progesterone analogues decreases macrophage Fcgamma receptors expression. Clin Immunol Immunopathol. 1998 Dec;89(3):231-9. PubMed PMID: 9837693. 5: Lipp R, Laurent H, Günther C, Riedl J, Esperling P, Täuber U. Prodrugs of gestodene for matrix-type transdermal drug delivery systems. Pharm Res. 1998 Sep;15(9):1419-24. PubMed PMID: 9755895. 6: Iguchi H, Ikeuchi T, Kai Y, Yoshida H. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism]. Hinyokika Kiyo. 1994 Mar;40(3):215-9. Japanese. PubMed PMID: 7513937. 7: Altwein JE, Almer F. Is there a change in the treatment of benign prostatic hyperplasia? Urol Int. 1994;52(1):1-3. PubMed PMID: 7511260. 8: Lang R, Reimann R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells. Environ Mol Mutagen. 1993;21(3):272-304. PubMed PMID: 8462531. 9: Di Silverio F, D'Eramo G, Flammia GP, Buscarini M, Frascaro E, Mariani M, Sciarra A. [Pharmacological combinations in the treatment of benign prostatic hypertrophy]. J Urol (Paris). 1993;99(6):316-20. Review. French. PubMed PMID: 7516378. 10: Kanimoto Y, Okada K. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results]. Hinyokika Kiyo. 1991 Nov;37(11):1423-8. Japanese. PubMed PMID: 1722627. 11: Adler A, Gillon G, Lurie H, Shaham J, Loven D, Shachter Y, Shani A, Servadio C, Stein JA. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod. 1987 Dec;6(6):610-24. PubMed PMID: 3330126. 12: Runge HM, Neumann HA, Bauknecht T, Pfleiderer A. Growth patterns and hormonal sensitivity of primary tumor, abdominal metastasis and ascitic fluid from human epithelial ovarian carcinomas in the tumor colony-forming assay. Eur J Cancer Clin Oncol. 1986 Jun;22(6):691-6. PubMed PMID: 3743604. 13: Di Silverio F. [Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate]. Minerva Urol Nefrol. 1986 Apr-Jun;38(2):163-71. Italian. PubMed PMID: 2428120. 14: Latalski M, Obuchowska D. [Ultrastructure of secretory cells of the bulbourethral glands of rats after experimental inhibition of the gonadotropic function of the pituitary gland]. Ann Univ Mariae Curie Sklodowska Med. 1986;41:139-44. Polish. PubMed PMID: 3154049. 15: Runge HM, Teufel G, Neulen J, Geyer H, Pfleiderer A. In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy. Cancer Chemother Pharmacol. 1986;16(1):58-63. PubMed PMID: 2933176. 16: Baranowska B, Kuzaka B. [Treatment of benign prostatic hypertrophy with gestonorone caproate]. Pol Tyg Lek. 1984 Jul 16-23;39(29-30):999-1003. Polish. PubMed PMID: 6209689. 17: De Palo G, Spatti GB, Bandieramonte G, Luciani L. Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion. Tumori. 1983 Feb 28;69(1):65-7. PubMed PMID: 6836750. 18: Moazzami B, Van der Walt JD, Boyd NR. Use of progestogens as an adjuvant to surgery in the treatment of stage I adenocarcinoma of the uterine corpus. Br J Obstet Gynaecol. 1983 Feb;90(2):178-81. PubMed PMID: 6218817. 19: Latalski M, Obuchowska D, Spruch T. [Study of the ultrastructure of epithelial cells of the seminal vesicles of rats after inhibition of the gonadotropic function of the anterior pituitary gland]. Ann Univ Mariae Curie Sklodowska Med. 1983;38:155-62. Polish. PubMed PMID: 6600062. 20: Turner GA, Ellis RD, Guthrie D, Latner AL, Ross WM, Skillen AW. Cyclic GMP in urine to monitor the response to ovarian cancer to therapy. Br J Obstet Gynaecol. 1982 Sep;89(9):760-4. PubMed PMID: 6288064.